Literature DB >> 7617794

Current benzodiazepine issues.

J H Woods1, G Winger.   

Abstract

This article deals with some of the recent evidence bearing on the issues of the liability of benzodiazepines to lead to abuse, dependence, and adverse behavioral effects. Reviews of epidemiological, clinical and experimental literature indicated that the previous conclusion about abuse of these drugs still holds: the vast majority of the use of benzodiazepines is appropriate. Problems of nonmedical use arise nearly exclusively among people who abuse other drugs. Nevertheless, there are reasons for concern about patients who take benzodiazepines regularly for long periods of time. These drugs can produce physiological dependence when taken chronically, and although this does not appear to result in dose escalation or other evidence of "psychological dependence," physiological dependence can result in patient discomfort if drug use is abruptly discontinued. Also, physicians are currently prescribing shorter-acting benzodiazepines in preference to longer-acting benzodiazepines. The shorter-acting drugs can produce a more intense withdrawal syndrome following chronic administration. Furthermore, rates of use of benzodiazepines increase with age, and elderly patients are more likely than younger ones to take the drug chronically. The clearest adverse effect of benzodiazepines is impairment of memory. This, too, may be particular concern in older patients whose recall in the absence of drug is typically impaired relative to younger individuals, and who are more compromised following drug administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617794     DOI: 10.1007/BF02245824

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  77 in total

1.  Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group.

Authors:  J A Grisso; J L Kelsey; B L Strom; G Y Chiu; G Maislin; L A O'Brien; S Hoffman; F Kaplan
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations.

Authors:  M Weintraub; S Singh; L Byrne; K Maharaj; L Guttmacher
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

Review 3.  Appropriate use and regulatory control of benzodiazepines.

Authors:  R I Shader; D J Greenblatt; M B Balter
Journal:  J Clin Pharmacol       Date:  1991-09       Impact factor: 3.126

4.  Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities.

Authors:  S G Zullich; T H Grasela; J B Fiedler-Kelly; F M Gengo
Journal:  Ann Pharmacother       Date:  1992-04       Impact factor: 3.154

Review 5.  Implications of altered drug disposition in the elderly: studies of benzodiazepines.

Authors:  D J Greenblatt; R I Shader; J S Harmatz
Journal:  J Clin Pharmacol       Date:  1989-10       Impact factor: 3.126

6.  Psychotropic drug use in a representative community sample: the Upper Bavarian study.

Authors:  M M Fichter; W Witzke; K Leibl; H Hippius
Journal:  Acta Psychiatr Scand       Date:  1989-07       Impact factor: 6.392

7.  Anxiety caused by a short-life hypnotic.

Authors:  K Morgan; I Oswald
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27

8.  Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients.

Authors:  K Rickels; W G Case; E E Schweizer; C Swenson; R B Fridman
Journal:  Psychopharmacol Bull       Date:  1986

9.  Patterns of psychotropic drug use in a Spanish rural community.

Authors:  J L Vázquez-Barquero; J F Diez Manrique; C Peña; A Arenal Gonzalez; M J Cuesta; J A Artal
Journal:  Br J Psychiatry       Date:  1989-11       Impact factor: 9.319

10.  Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community.

Authors:  M Swartz; R Landerman; L K George; M L Melville; D Blazer; K Smith
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

View more
  19 in total

Review 1.  Hypnotics: an update.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  Ramelteon: a novel hypnotic indicated for the treatment of insomnia.

Authors:  Gary K Zammit
Journal:  Psychiatry (Edgmont)       Date:  2007-09

3.  The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: prevalence of co-occurrence in a national sample.

Authors:  Sean Esteban McCabe; James A Cranford; Carol J Boyd
Journal:  Drug Alcohol Depend       Date:  2006-04-18       Impact factor: 4.492

4.  Correlates of nonmedical use of prescription benzodiazepine anxiolytics: results from a national survey of U.S. college students.

Authors:  Sean Esteban McCabe
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

5.  Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; Surilla Randall; Erica Harris; Renee Maan; Thomas Roth
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

Review 6.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 7.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

8.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 9.  Addiction to benzodiazepines.

Authors:  C Salzman
Journal:  Psychiatr Q       Date:  1998

Review 10.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.